Porcine Relaxin but Not Serelaxin Shows Residual Bioactivity after In Vitro Simulated Intestinal Digestion—Clues for the Development of New Relaxin Peptide Agonists Suitable for Oral Delivery

Despite human recombinant H2 relaxin or serelaxin holding promise as a cardiovascular drug, its actual efficacy in chronic treatment of heart failure patients was hampered by the need to be administered by multiple daily IV injections for a long time, with obvious drawbacks in terms of patients’ com...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacini, Lorenzo, D’Ercole, Annunziata, Papini, Anna Maria, Bani, Daniele, Nistri, Silvia, Rovero, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820531/
https://www.ncbi.nlm.nih.gov/pubmed/36613489
http://dx.doi.org/10.3390/ijms24010048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820531/
https://www.ncbi.nlm.nih.gov/pubmed/36613489
http://dx.doi.org/10.3390/ijms24010048

Ejemplares similares